Horizon Pharma plc and XL-protein GmbH have entered into a collaboration agreement on a potential next-generation biologic for uncontrolled gout using PASylation® technology
FREISING, January 9, 2018 /XL-protein/ -- Horizon Pharma plc…
AdAlta and XL-protein execute commercial license agreement
FREISING Germany, 13 November, 2017: XL-protein GmbH is pleased…
Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
Freising, July 26, 2017 /XL-protein/ -- Jazz Pharmaceuticals…